Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 26, 2012. The report details a specific share repurchase transaction executed under shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 800,000 Ordinary Shares of 25 pence each.
- Purchase Date: September 26, 2012.
- Price Range: Highest price paid was 1,456 pence per share; lowest price paid was 1,443 pence per share.
- Treasury Holdings (Settled): 497,015,427 shares (9.13% of total issued share capital).
- Treasury Holdings (Including Unsettled): 499,865,427 shares (10.10% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,947,056,747 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 800,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.10% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. It explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (497,015,427 settled) against the company's latest capitalization table.
- Confirm the calculation of total voting rights (10.10% held in Treasury including unsettled shares) for disclosure threshold assessments.
- Check the price paid per share (1,443 to 1,456 pence) against market trading data for September 26, 2012.
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial statements.